Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:39:08 ON 17 APR 2008

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:39:17 ON 17 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8
DICTIONARY FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573274c.str



chain nodes :
10 12 13 20
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19
chain bonds :
1-10 10-13 10-12 10-14 17-20
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 14-15 14-19 15-16 16-17 17-18
18-19
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 17-20
exact bonds :
10-13 10-12 10-14
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :
containing 1 : 14 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 11:39:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12365 TO ITERATE

100.0% PROCESSED 12365 ITERATIONS 2072 ANSWERS
SEARCH TIME: 00.00.01

L2 2072 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 11:39:41 ON 17 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 16 Apr 2008 (20080416/ED)


```
=> s l2 full
L3          359 L2

=> s l3 and py<2003
      22929815 PY<2003
L4          284 L3 AND PY<2003

=> d ibib abs hitstr 1-10
```

L4 ANSWER 1 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1149384 CAPLUS
DOCUMENT NUMBER: 143:399873
TITLE: Use of AT1 receptor antagonists or AT2 receptor modulators for the treatment of conditions or diseases associated with the increase of AT1 or AT2 receptors.
INVENTOR(S): Ganter, Sabina Maria; Wagner, Robert Frank
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1588706	A2	20051026	EP 2005-13209	19991222
EP 1588706	A3	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
EP 1013273	A1	20000628	EP 1998-811258	19981223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6465502	B1	20021015	US 1999-468663	19991221 <--
EP 1140071	A1	20011010	EP 1999-964665	19991222 <--
EP 1140071	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
SG 120119	A1	20060328	SG 2003-5638	19991222
ZA 2001004299	A	20020528	ZA 2001-4299	20010525 <--
US 20020155986	A1	20021024	US 2002-72516	20020206 <--
AU 2003266433	A1	20040108	AU 2003-266433	20031202
AU 2006203077	A1	20060810	AU 2006-203077	20060718

PRIORITY APPLN. INFO.:		
EP 1998-811257	A	19981223
EP 1998-811258	A	19981223
EP 1999-964665	A3	19991222
US 1999-468663	A3	19991221
AU 2000-30430	A3	19991222
WO 1999-EP10330	W	19991222
AU 2003-266433	A3	20031202

AB The invention relates to the use of an AT1 receptor antagonist or or an AT2 receptor modulator, resp., or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia. Valsartan formulations are included.
IT 135070-05-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AT1 receptor antagonists or AT2 receptor modulators for treatment of conditions associated with increase of AT1 or AT2 receptors)
RN 135070-05-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)


Me
N
N
N
CH2
HO2C

L4 ANSWER 2 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:264243 CAPLUS
DOCUMENT NUMBER: 140:270847
TITLE: Preparation of antidiabetic 5-(heterocyclylmethoxybenzyl)thiazolidine-2,4-diones and their intermediates
INVENTOR(S): Fujita, Takashi; Yoshioka, Takao; Fujiwara, Toshihiko; Oguchi, Minoru; Yanagisawa, Hiroaki; Horikoshi, Hiroyoshi; Wada, Kunio; Fujimoto, Koichi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: U.S., 87 pp., Division of U.S. 5,624,935.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5739345	A	19980414	US 1996-745377	19961108 <--
HU 72627	A2	19960528	HU 1995-2600	19950411 <--
US 5624935	A	19970429	US 1995-419919	19950411 <--
IL 115269	A	19990620	IL 1995-115269	19950912 <--
US 5834501	A	19981110	US 1996-713543	19960913 <--
US 5962470	A	19991005	US 1997-1093	19971230 <--
US 5977365	A	19991102	US 1998-110693	19980707 <--
AU 9887093	A	19981203	AU 1998-87093	19980928 <--
AU 712294	B2	19991104		
US 6117893	A	20000912	US 1999-261645	19990303 <--
PRIORITY APPLN. INFO.:			JP 1994-72083 A	19940411
			US 1995-419919 A3	19950411
			IL 1995-113313 A3	19950410
			HU 1995-1040 A	19950411
			US 1996-713543 A3	19960913
			AU 1997-32443 A3	19970801
			US 1997-1093 A3	19971230

OTHER SOURCE(S): MARPAT 140:270847
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = (un)substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl, or imidazopyrimidinyl; Y = O or S; Z = 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl; R = H, (ar)alkyl, alkoxy, halo, OH, NO2, or (un)substituted amino; m = 1-5; and salts thereof] were prepared as hypoglycemic and antidiabetic agents. Also disclosed are intermediate compds. II [wherein Q = alkoxycarbonyl, CHO, CO2H, or OH; Y = O or S; Y' = S; R = H, (ar)alkyl, alkoxy, halo, OH, NO2, or (un)substituted amino; m = 1-5; and salts thereof] for the preparation of I. For example, 5-chloro-2-hydroxymethyl-3-methylimidazo[5,4-b]pyridine was condensed with 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione in the presence of PBu3 and 1,1'-(azodicarbonyl)dipiperidine in THF to give 5-[4-(5-chloro-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl]-3-triphenylmethylthiazolidine-2,4-dione. Deprotection using AcOH and H2O provided III, which lowered blood glucose levels in hyperglycemic male KK mice by 37.1% at a dose of 1 mg/kg and inhibited aldose reductase activity with IC50 of 1.8 μM/mL. In toxicity expts., oral administration of 50

mg/kg III to ohm male F344 rats for 2 wk produced no abnormalities and resulted in a zero mortality rate.

IT 172647-68-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

RN 172647-68-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-([1,1'-biphenyl]-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methoxy]phenyl]methyl]- (CA INDEX NAME)



IT 172648-17-8P 172648-18-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

RN 172648-17-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-2-methanol, 3-([1,1'-biphenyl]-4-ylmethyl)- (CA INDEX NAME)



RN 172648-18-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-([1,1'-biphenyl]-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methoxy]phenyl]methyl]-3-(triphenylmethyl)- (CA INDEX NAME)





REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:112122 CAPLUS
DOCUMENT NUMBER: 139:239629
TITLE: CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists
AUTHOR(S): Datar, Prasanna; Desai, Prashant; Coutinho, Evans; Iyer, Krishna
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Mumbai, 400 098, India
SOURCE: Journal of Molecular Modeling (2002), 8(10), 290-301
CODEN: JMMOFK; ISSN: 0948-5023
URL: http://link.springer.de/link/service/journals/00894/contents/02/00097/paper/s00894-002-0097-6.pdf
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

AB Two 3D-QSAR methods CoMFA and CoMSIA were applied to a set of 38 angiotensin receptor(AT1) antagonists. The conformation and alignment of mols. were obtained by a novel method consensus dynamics. The representation of biol. activity, partial charge formalism, absolute orientation of the mols. in the grid, and grid spacing were also studied for their effect on the CoMFA models. The models were thoroughly validated through trials using scrambled activities and bootstrapping. The best CoMFA model had across-validated correlation coefficient (q2) of 0.632, which improved with "region focusing" to 0.680. This model had a "predictive" r2 of 0.436 on a test series that was unique and with little representation in the training set. Although the "predictive" r2 of the best CoMSIA model, which included steric, electrostatic, and hydrogen bond acceptor fields was higher than that of the best CoMFA model, the other statistical parameters like q2, r2, F value, and s were unsatisfactory. The contour maps generated using the best CoMFA model were used to identify the structural features important for biol. activity in these compds.

IT 133240-37-6 133240-38-7 133240-46-7
133241-05-1 157263-00-8 158963-52-1
158963-53-2 158963-54-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists)

RN 133240-37-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 133240-38-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 7-methyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 133240-46-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 133241-05-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 157263-00-8 CAPLUS
CN Benzamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 158963-52-1 CAPLUS
CN Acetamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 158963-53-2 CAPLUS
CN Butanamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)



RN 158963-54-3 CAPLUS
CN Propanamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:888552 CAPLUS
DOCUMENT NUMBER: 137:380012
TITLE: Method of treatment for prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function
INVENTOR(S): Shahinfar, Shahnaz; Brenner, Barry M.; Zhang, Zhongxin
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092081	A1	20021121	WO 2002-US14919	20020510 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002303711	A1	20021125	AU 2002-303711	20020510 <--
US 20030073705	A1	20030417	US 2002-143415	20020510
CA 2445913	A1	20031029	CA 2002-2445913	20020510
EP 1389105	A1	20040218	EP 2002-731759	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005501815	T	20050120	JP 2002-588998	20020510
PRIORITY APPLN. INFO.:			US 2001-290839P	P 20010514
			WO 2002-US14919	W 20020510

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[((2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4, -b]pyridine, or pharmaceutically acceptable salts thereof are useful.

IT 133240-46-7 135070-05-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 133240-46-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 135070-05-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:870449 CAPLUS
DOCUMENT NUMBER: 139:95083
TITLE: How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach
AUTHOR(S): Zoja, Carla; Corna, Daniela; Camozzi, Davide; Cattaneo, Dario; Rottoli, Daniela; Batani, Cristian; Zanchi, Cristina; Abbate, Mauro; Remuzzi, Giuseppe
CORPORATE SOURCE: Mario Negri Institute for Pharmacological Research, Bergamo, Italy
SOURCE: Journal of the American Society of Nephrology (2002), 13(12), 2898-2908
CODEN: JASNEU; ISSN: 1046-6673
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158809; 0.3 mg/kg lisinopril plus L-158809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased threefold in PHN, it was inhibited by more than 60% after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30%. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-β1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-β1 gene upregulation by 25%. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.
IT 133240-46-7, L-158809
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACE inhibitor and angiotensin II receptor antagonist and statin full protection of kidney in rats with Heymann nephritis)
RN 133240-46-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:849376 CAPLUS
DOCUMENT NUMBER: 137:358120
TITLE: Compositions and methods for treating colorectal polyps and cancer
INVENTOR(S): Tamura, Masaaki
PATENT ASSIGNEE(S): Vanderbilt University, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087503	A2	20021107	WO 2002-US13383	20020426 <--
WO 2002087503	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002311859	A1	20021111	AU 2002-311859	20020426 <--
US 20030083339	A1	20030501	US 2002-133056	20020426
PRIORITY APPLN. INFO.:			US 2001-286621P	P 20010426
			WO 2002-US13383	W 20020426

AB A method of decreasing a biol. function of an AT2 receptor in a subject in need thereof is disclosed . The method includes administering an effective amount of a therapeutic agent such as PD123319 to the subject to decrease a biol. function of an AT2 receptor. Cancer therapy, particularly colorectal cancer therapy, by the method is also disclosed.

IT 135070-05-2, e4177
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treating colorectal polyps and cancer)

RN 135070-05-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

L4 ANSWER 7 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:755214 CAPLUS
DOCUMENT NUMBER: 137:263024
TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143024	A1	20021003	US 2000-737201	20001214 <--
US 6638937	B2	20031028		
EP 1741713	A2	20070110	EP 2006-16968	20001213
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
ES 2273739	T3	20070516	ES 2000-984282	20001213
US 20040106833	A1	20040603	US 2003-673100	20030926
US 6835741	B2	20041228		
US 20040127515	A1	20040701	US 2003-672572	20030926
US 6852745	B2	20050208		

PRIORITY APPLN. INFO.:

US 1998-91847P	P	19980706
US 1999-345392	B2	19990701
US 1999-464037	B2	19991215
US 2000-481197	B2	20000111
US 2000-513779	A2	20000225
US 2000-604322	A2	20000626
US 2000-643640	B2	20000822
EP 2000-984282	A3	20001213
US 2000-737201	A3	20001214

OTHER SOURCE(S): MARPAT 137:263024
GI



I

AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyloxy, etc.; R2 = H, halo,

CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO2, etc; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

IT 254738-03-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-07-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254738-09-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254738-88-0P, Butanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254738-98-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254739-02-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254739-04-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254740-01-7P , Acetamide, N-[2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254740-02-8P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254740-45-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254740-48-2P , [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254740-49-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254741-26-9P, Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254741-37-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-43-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254742-85-3P , Acetamide, N-[2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254742-86-4P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254738-03-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254738-07-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 254738-09-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- (CA INDEX NAME)



RN 254738-88-0 CAPLUS
CN Butanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- (CA INDEX NAME)



RN 254738-98-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254739-02-1 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254739-04-3 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 254740-01-7 CAPLUS
CN Acetamide, N-[2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- (CA INDEX NAME)



RN 254740-02-8 CAPLUS
CN [1,1'-Biphenyl]-2-acetic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester (CA INDEX NAME)



RN 254740-45-9 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254740-48-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 254740-49-3 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- (CA INDEX NAME)



RN 254741-26-9 CAPLUS
CN Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- (CA INDEX NAME)



RN 254741-37-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254741-41-8 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



RN 254741-43-0 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 254742-85-3 CAPLUS
CN Acetamide, N-[2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- (CA INDEX NAME)



RN 254742-86-4 CAPLUS
CN [1,1'-Biphenyl]-2-acetic acid, 2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester (CA INDEX NAME)



IT 254744-84-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-

methoxyethoxy)methyl]- 254745-03-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-formyl-N-[(2-methoxyethoxy)methyl]- 254745-06-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254745-08-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254744-84-8 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]- (CA INDEX NAME)



RN 254745-03-4 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-formyl-N-[(2-methoxyethoxy)methyl]- (CA INDEX NAME)



RN 254745-06-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 254745-08-9 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:663891 CAPLUS
DOCUMENT NUMBER: 138:297281
TITLE: Effects of SK-1080 on intimal thickening and impaired vascular relaxation after balloon injury in rats
AUTHOR(S): Lee, Byung Ho; Yoo, Sung-Eun; Shin, Hwa Sup
CORPORATE SOURCE: Screening and Toxicology Research Center, Korea Research Institute of Chemical Technology, Taejon, S. Korea
SOURCE: Pharmacology (2002), 66(2), 81-88
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of SK-1080, a novel angiotensin AT1 receptor antagonist, on neointimal proliferation were investigated in the rat carotid artery after balloon injury, together with its effects on the impaired endothelium-dependent vascular relaxation. SK-1080 (0.3 and 1.0 mg/kg/day) was orally administered to balloon-injured rats for 21 days (from 6 days before to 14 days after balloon injury). SK-1080 (1 mg/kg) exerted effects on three important parameters associated with the intimal thickening induced by balloon injury (50.0% reduction in neointimal area, 42.7% reduction in stenosis and 69.1% increase in lumen/total area ratio). Acetylcholine-induced relaxation was reduced in the balloon-injured carotid arteries, and this impairment was counteracted by SK-1080. However, endothelial-independent, sodium nitroprusside-induced relaxation was present and did not differ among the carotid arteries from all the treatment groups. Furthermore, acetylcholine-induced relaxation was completely inhibited by L-NAME but not by indomethacin. SK-1080 caused a slight hypotension 1 day before balloon injury, which gradually returned to basal values 6 and 13 days after balloon injury. SK-1080 may have therapeutic potential for the treatment of vascular diseases such as restenosis and atherosclerosis.

IT 174800-22-7, SK 1080
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin AT1 receptor antagonist SK-1080 effects on intimal thickening and impaired vascular relaxation after balloon injury)

RN 174800-22-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-butyl-5-methyl-6-(1-oxido-2-pyridinyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:575196 CAPLUS
DOCUMENT NUMBER: 137:137277
TITLE: Constitutively desensitized g protein-coupled receptors
INVENTOR(S): Barak, Larry S.; Oakley, Robert H.; Caron, Marc G.; Laporte, Stephane A.; Wilbanks, Alyson
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059267	A2	20020801	WO 2002-US1701	20020123 <--
WO 2002059267	A3	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030049643	A1	20030313	US 2002-54616	20020122
US 7279324	B2	20071009		
CA 2435047	A1	20020801	CA 2002-2435047	20020123 <--
AU 2002245290	A1	20020806	AU 2002-245290	20020123 <--
EP 1368378	A2	20031210	EP 2002-713440	20020123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524834	T	20040819	JP 2002-559554	20020123
PRIORITY APPLN. INFO.:			US 2001-263406P	P 20010123
			US 2002-54616	A 20020122
			WO 2002-US1701	W 20020123

AB The invention concerns modified G-protein coupled receptors (GPCRs). The modified GPCRs of the present invention include GPCRs that have been modified to have altered DRY motifs such that the modified GPCRs are constitutively desensitized. As such, the modified GPCRs of the present invention preferably localize to endocytic vesicles or endosomes in an agonist-independent manner. The invention also relates to methods of screening compds. and sample solns. for GPCR activity using the modified GPCRs.

IT 133240-46-7
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(constitutively desensitized g protein-coupled receptors)

RN 133240-46-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)


Me
N
Et
N
N
N
HN
N
Me
N
CH2

L4 ANSWER 10 OF 284 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:556104 CAPLUS
DOCUMENT NUMBER: 137:109489
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., which which which which which which which which which which which which which which which w
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 27
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20020099013	A1	20020725	US 2001-933708		20010822	<--
US 20040087483	A1	20040506	US 2002-136433		20020502	
US 7163918	B2	20070116				
US 20040063628	A1	20040401	US 2002-156527		20020529	
US 7060708	B2	20060613				
IN 2003KN00775	A	20050204	IN 2003-KN775		20030613	
US 20070232529	A1	20071004	US 2004-923088		20040823	
US 20060014697	A1	20060119	US 2005-89056		20050325	
US 20070060500	A1	20070315	US 2006-392878		20060330	
US 20080086016	A1	20080410	US 2007-745019		20070507	
AU 2007203485	A1	20070816	AU 2007-203485		20070726	
PRIORITY APPLN. INFO.:			US 2000-247556P	P	20001114	
			US 2000-247558P	P	20001114	
			US 2000-247559P	P	20001114	
			US 2000-247560P	P	20001114	
			US 2000-247561P	P	20001114	
			US 2000-247594P	P	20001114	
			US 2000-247595P	P	20001114	
			US 2000-247606P	P	20001114	
			US 2000-247607P	P	20001114	
			US 2000-247608P	P	20001114	
			US 2000-247609P	P	20001114	
			US 2000-247610P	P	20001114	
			US 2000-247611P	P	20001114	
			US 2000-247612P	P	20001114	
			US 2000-247620P	P	20001114	
			US 2000-247621P	P	20001114	
			US 2000-247634P	P	20001114	
			US 2000-247635P	P	20001114	
			US 2000-247698P	P	20001114	
			US 2000-247699P	P	20001114	
			US 2000-247700P	P	20001114	
			US 2000-247701P	P	20001114	
			US 2000-247702P	P	20001114	
			US 2000-247797P	P	20001114	
			US 2000-247798P	P	20001114	
			US 2000-247799P	P	20001114	
			US 2000-247800P	P	20001114	
			US 2000-247801P	P	20001114	
			US 2000-247802P	P	20001114	
			US 2000-247803P	P	20001114	
			US 2000-247804P	P	20001114	
			US 2000-247805P	P	20001114	

US 2000-247807P	P	20001114
US 2000-247832P	P	20001114
US 2000-247833P	P	20001114
US 2000-247926P	P	20001114
US 2000-247927P	P	20001114
US 2000-247928P	P	20001114
US 2000-247929P	P	20001114
US 2000-247930P	P	20001114
US 1999-265415	B2	19990310
US 1999-411238	B2	19991004
WO 2000-US5693	A	20000306
US 2000-642820	A2	20000822
US 2000-247684P	P	20001114
US 2000-248527P	P	20001116
US 2000-248528P	P	20001116
US 2000-248529P	P	20001116
US 2000-248530P	P	20001116
US 2000-248531P	P	20001116
US 2000-248532P	P	20001116
US 2000-248533P	P	20001116
US 2000-248535P	P	20001116
US 2000-248536P	P	20001116
US 2000-248537P	P	20001116
US 2000-248538P	P	20001116
US 2000-248539P	P	20001116
US 2000-248540P	P	20001116
US 2000-248607P	P	20001116
US 2000-248620P	P	20001116
US 2000-248660P	P	20001116
US 2000-248662P	P	20001116
US 2000-248663P	P	20001116
US 2000-248685P	P	20001116
US 2000-248713P	P	20001116
US 2000-248714P	P	20001116
US 2000-248715P	P	20001116
US 2000-248716P	P	20001116
US 2000-248717P	P	20001116
US 2000-248721P	P	20001116
US 2000-248722P	P	20001116
US 2000-248723P	P	20001116
US 2000-248724P	P	20001116
US 2000-248725P	P	20001116
US 2000-248726P	P	20001116
US 2000-248727P	P	20001116
US 2000-248728P	P	20001116
US 2000-248729P	P	20001116
US 2000-248730P	P	20001116
US 2000-248731P	P	20001116
US 2000-248732P	P	20001116
US 2000-248733P	P	20001116
US 2000-248737P	P	20001116
US 2000-248738P	P	20001116
US 2000-248748P	P	20001116
US 2000-248764P	P	20001116
US 2000-248765P	P	20001116
US 2000-248767P	P	20001116
US 2000-248768P	P	20001116
US 2000-248769P	P	20001116
US 2000-248770P	P	20001116
US 2000-248771P	P	20001116
US 2000-248772P	P	20001116
US 2000-248774P	P	20001116

US 2000-248776P	P	20001116
US 2000-248777P	P	20001116
US 2000-248778P	P	20001116
US 2000-248779P	P	20001116
US 2000-248781P	P	20001116
US 2000-248782P	P	20001116
US 2000-248783P	P	20001116
US 2000-248787P	P	20001116
US 2000-248794P	P	20001116
US 2000-248795P	P	20001116
US 2000-248796P	P	20001116
US 2000-248797P	P	20001116
US 2000-248833P	P	20001116
US 2001-933708	A2	20010822
US 2001-986426	A2	20011108
AU 2001-298033	A3	20011114
US 2001-987458	B2	20011114
WO 2001-US43089	B2	20011114
US 2001-988034	B2	20011116
US 2001-988071	B2	20011116
WO 2001-US43115	B2	20011116
WO 2001-US43117	B2	20011116
US 2002-358368P	P	20020222
US 2002-358381P	P	20020222
US 2002-362082P	P	20020307
US 2002-366258P	P	20020322
US 2002-156527	A2	20020529
WO 2003-US5524	A2	20030224
WO 2003-US5525	A2	20030224
US 2003-507012P	P	20030930
US 2003-727565	A2	20031205
US 2004-567800P	P	20040505
US 2004-567802P	P	20040505
US 2004-568011P	P	20040505
US 2004-857619	A3	20040601
US 2004-923088	A2	20040823
US 2004-923257	A2	20040823
US 2004-953110	A2	20040930
US 2004-953111	A2	20040930
US 2004-953116	A2	20040930
US 2004-953119	A2	20040930
US 2004-955006	A2	20040930
WO 2004-US32131	A2	20040930

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

IT 157263-00-8, L 159282
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

RN 157263-00-8 CAPLUS

CN Benzamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (CA INDEX NAME)


Me
N
Et
O
NH
C
Ph
O
S
N
CH2
Me
N
O

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              59.98     238.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -8.00      -8.00

STN INTERNATIONAL LOGOFF AT 11:44:05 ON 17 APR 2008
```